The Daily Ledger

HealthNews

Daily GLP-1 pills raise hopes of closing diabetes care gap

Once-daily GLP-1 tablets could be cheaper and easier to store than injections, Al Jazeera reports. WHO backs the drugs conditionally but projects they will reach fewer than 10% of those who could benefit by 2030.

The Daily Ledger Staff · Updated 4 min read

Daily pills are starting to join weekly injections in the fast-growing class of GLP-1 medicines used for type 2 diabetes and obesity. On World Diabetes Day, 14 November, Al Jazeera examined whether cheaper, easier-to-store tablets could widen access in lower-income countries, where the injectable versions remain out of reach for many patients. The World Health Organization (WHO) has already warned that access to these medicines is likely to stay limited for years.

What is confirmed

  • WHO backs the medicines, with conditions. In a guideline issued on 1 December 2025, WHO conditionally recommended that GLP-1 therapies may be used by adults, excluding pregnant women, for the long-term treatment of obesity. The guideline covers liraglutide, semaglutide and tirzepatide.
  • The health burden is large. WHO says obesity affects more than 1 billion people and was associated with 3.7 million deaths worldwide in 2024, a figure also cited by Al Jazeera.
  • Diabetes use is already recognised. WHO says it added GLP-1 therapies to its Essential Medicines List in September 2025 for managing type 2 diabetes in high-risk groups.
  • Supply will fall short. Even with rapid growth in production, WHO projects the therapies will reach fewer than 10% of the people who could benefit by 2030.

Why pills could matter

According to Al Jazeera, the market has been dominated by weekly injections such as Ozempic, Wegovy and Mounjaro, but once-daily oral versions are becoming more widely available. The outlet reports that tablets could be cheaper and need less cold-chain storage, a practical advantage in emerging economies.

Al Jazeera also reports wide price differences. It puts the monthly cost of Mounjaro at about $500 in the United States, $264 in the United Kingdom, $336 in Saudi Arabia and $157 in India. In Pakistan, the imported product is reported to cost $723, against $61 for a locally made tirzepatide, while locally manufactured oral semaglutide is priced at about $18 for a 30-day supply. These figures come from a single report and have not been independently confirmed here.

The same report says Pakistan has the world's highest diabetes prevalence, at 31.4 percent, and that one in nine people aged 20 to 79 worldwide has diabetes.

The limits of tablets

Pills are not a simple substitute. Al Jazeera notes that oral semaglutide has to be taken on an empty stomach and at a higher dose, while newer tablets such as orforglipron can be taken without fasting. It adds that few head-to-head trials have compared pills with injections.

WHO's access warning

WHO made its recommendation conditional because of limited long-term data on efficacy and safety, current costs, weak health-system preparedness and equity concerns. It says that without deliberate policies, access could widen existing health disparities, and it suggests pooled procurement, tiered pricing and voluntary licensing as ways to broaden supply.

"While medication alone won't solve this global health crisis, GLP-1 therapies can help millions overcome obesity," WHO Director-General Dr Tedros Adhanom Ghebreyesus said when the guideline was issued.

The agency also warns that demand has fuelled falsified and substandard products, and says the medicines should be prescribed by qualified health professionals through regulated channels.

Claims that go beyond the evidence

Interest in the drugs now extends well past diabetes and weight loss. Scientific American reported on 12 November that some telehealth companies promote "microdoses", amounts below the minimum approved dose, as a route to a longer life. Researchers quoted by the magazine urged caution. A mouse study published in Nature in September 2026 found that semaglutide-treated mice lived longer, but lead researcher Danica Chen of the University of California, Berkeley, told the magazine it is not known whether microdosing would bring the same benefits, and that nothing can be said for sure without human data.

Michael Corley, an aging researcher at the University of California, San Diego, told Scientific American he would not recommend microdosing at this point, noting that many such products are compounded and not regulated in the same way as approved drugs.

Analysis: price is only one barrier

Analysis: Taken together, the reports suggest that lower-cost tablets could remove some obstacles, such as refrigeration and injection, but not all of them. WHO's own projection of under 10% coverage by 2030 points to manufacturing capacity and health-system readiness as constraints that a change of formulation alone will not solve. Industry forecasts cited by Al Jazeera, which has Eli Lilly and Novo Nordisk expecting the market to grow from $80bn a year to $135bn by 2030, are projections rather than outcomes. How far locally made pills close the treatment gap will depend on regulation, quality control and how governments choose to prioritise patients.

Sources

Written with automated tools from the sources above and published without editor review. Spotted an error? Tell us · Corrections Policy

Report a problem with this story · Copyright & takedown